CAM
NVAX icon

Cresset Asset Management’s Novavax NVAX Stock Holding History

Cresset Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-53,466
Closed -$256K – 2151
2024
Q1 		$256K Buy
53,466
+2,754
+5% +$12.8K ﹤0.01% 1658
2023
Q4 		$243K Buy
50,712
+700
+1% +$4.29K ﹤0.01% 1595
2023
Q3 		$362K Sell
50,012
-1,854
-4% -$14.8K ﹤0.01% 1351
2023
Q2 		$385K Buy
+51,866
New +$408K ﹤0.01% 1401

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Cresset Asset Management's NVAX Position: Q2 2024 in Review

Cresset Asset Management sold out of Novavax (NVAX) in Q2 2024, closing a stake of 53,466 shares — an estimated $256K sold.

Cresset Asset Management first reported a position in NVAX in Q2 2023 and held it in 4 quarters. The position peaked at $385K in Q2 2023. 229 funds tracked by Wall St. Rank hold NVAX as of Q2 2024.

  • Cresset Asset Management reported no remaining Novavax position as of Q2 2024 after selling out during the quarter.
  • Cresset Asset Management sold 53,466 Novavax shares in Q2 2024, an estimated $256K.
  • Cresset Asset Management first reported a position in Novavax in Q2 2023 and held it in 4 quarters.
  • Cresset Asset Management's Novavax position peaked at $385K in Q2 2023.
  • 229 funds tracked by Wall St. Rank held Novavax as of Q2 2024.

Based on Cresset Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.